Alternative splicing of the human glucocorticoid receptor (hGR) primary transcript produces two highly homologous protein isoforms, termed hGR␣ and hGR␤, that differ at their carboxy-termini. In contrast to the well characterized hGR␣ isoform, which modulates gene expression in a hormone-dependent fashion, the biological significance of hGR␤ has only recently begun to emerge. We and others have shown that the hGR␤ messenger RNA transcript is widely expressed in human tissues and that the hGR␤ protein functions as a dominant negative inhibitor of hGR␣ in transfected cells. Unfortunately, these initial studies did not determine whether the hGR␤ protein was made in vivo. Such analyses are hindered because available anti-hGR antibodies cannot discriminate between the similarly sized hGR␣ and hGR␤ proteins. Therefore, to investigate the expression of the hGR␤ protein, we have produced an antipeptide, hGR␤-specific antibody termed BShGR. This antibody was made against the unique 15-amino acid peptide at the carboxy-terminus of hGR␤ and recognizes both the native and denatured conformations of hGR␤, but does not cross-react with hGR␣. Using BShGR on Western blots and in immunoprecipitation experiments, we detected the hGR␤ protein in a variety of human cell lines and tissues. Immunocytochemistry was then performed with BShGR on HeLa S 3 and CEM-C7 cells and on tissue sections prepared from lung, thymus, and liver to assess the cellular and subcellular distribution of hGR␤. In all immunopositive cells, hGR␤ was found in the nucleus independent of glucocorticoid treatment. Within tissues, the hGR␤ protein was expressed most abundantly in the epithelial cells lining the terminal bronchiole of the lung, forming the outer layer of Hassall's corpuscle in the thymus, and lining the bile duct in the liver. As a potential in vivo inhibitor of hGR␣ activity, expression of hGR␤ may be an important factor regulating target cell responsiveness to glucocorticoids. (Endocrinology 138: 5028 -5038, 1997) 
unique 15-amino acid peptide at the carboxy-terminus of hGR␤ and recognizes both the native and denatured conformations of hGR␤, but does not cross-react with hGR␣. Using BShGR on Western blots and in immunoprecipitation experiments, we detected the hGR␤ protein in a variety of human cell lines and tissues. Immunocytochemistry was then performed with BShGR on HeLa S 3 and CEM-C7 cells and on tissue sections prepared from lung, thymus, and liver to assess the cellular and subcellular distribution of hGR␤. In all immunopositive cells, hGR␤ was found in the nucleus independent of glucocorticoid treatment. Within tissues, the hGR␤ protein was expressed most abundantly in the epithelial cells lining the terminal bronchiole of the lung, forming the outer layer of Hassall's corpuscle in the thymus, and lining the bile duct in the liver. As a potential in vivo inhibitor of hGR␣ activity, expression of hGR␤ may be an important factor regulating target cell responsiveness to glucocorticoids. (Endocrinology 138: 5028 -5038, 1997) T HE GLUCOCORTICOID receptor (GR) belongs to the superfamily of steroid/thyroid/retinoic acid receptor proteins that function as ligand-dependent transcription factors (1) (2) (3) . Like other members of this family, the GR is comprised of an amino-terminal trans-activation domain, a central DNA-binding domain, and a carboxy-terminus that contains the hormone-binding domain as well as sequences important for interacting with heat shock protein-90 (hsp90) (4), nuclear translocation (5), receptor dimerization (6) , and trans-activation (7) . In the absence of ligand, the GR resides in the cytoplasm of cells in a multiprotein complex consisting of the receptor polypeptide, two molecules of hsp90, and several additional proteins (8, 9) . The receptor undergoes a change in conformation upon hormone binding, resulting in the dissociation of hsp90 and the other associated proteins. In its new conformation, the activated GR translocates into the nucleus, where it binds to glucocorticoid receptor-responsive elements (GREs) located in the promoter regions of target genes. The receptor then communicates with the basal transcription machinery and either positively or negatively regulates expression of the linked gene depending on the GRE sequence and promoter context. The activated GR can also modulate gene expression apart from DNA binding by physically interacting with other transcription factors, such as activating protein-1 and nuclear factor-B (10 -13) .
When the human GR (hGR) complementary DNA (cDNA) was cloned in 1985, two cDNA clones were isolated that predicted the existence of two highly homologous receptor isoforms differing only at their carboxy-termini (14) . These two isoforms, termed hGR␣ and hGR␤, are identical through amino acid 727, but then diverge, with hGR␣ having an additional 50 amino acids and hGR␤ having an additional, nonhomologous 15 amino acids. Alternative splicing in exon 9 of the hGR gene was later shown to be responsible for generating the two receptor isoforms (15) . Over the last decade, investigators have focused their attention on hGR␣, which, as described above, functions as a ligand-dependent transcription factor. In contrast, the hGR␤ isoform has been largely ignored because early studies reported that the recombinant hGR␤ protein did not bind hormone and did not activate glucocorticoid-responsive promoters (14, 16) .
Two recent findings have sparked new interest into the role hGR␤ may play in steroid receptor physiology. First, the hGR␤ messenger RNA (mRNA) transcript, like hGR␣, has a widespread tissue distribution (15, 17) . Second, the recombinant hGR␤ protein inhibits hGR␣-mediated trans-activation of target genes in a dose-dependent manner (15, 17) . The mechanism responsible for this inhibition has not been elucidated, but may involve competition between hGR␣ and hGR␤ for GRE binding, formation of hGR␣/hGR␤ heterodimers that are transcriptionally inactive, and/or titration of a coactivator needed by hGR␣ for full transcriptional activity. The ability of hGR␤ to antagonize the function of hGR␣ suggests that hGR␤ may be a critical factor regulating target cell responsiveness to glucocorticoids. High levels of hGR␤ would confer glucocorticoid resistance and low levels of hGR␤ would confer glucocorticoid hypersensitivity.
Although the hGR␤ mRNA transcript has been detected in many tissues, it is still not known whether this message is actually translated into endogenous hGR␤ protein. Resolving this fundamental issue is critical to further understanding the role hGR␤ plays in vivo. Investigating hGR␤ protein expression is problematic because no ligand has been identified for hGR␤ and all anti-hGR antibodies currently in use recognize both 94-kDa hGR␣ and 90-kDa hGR␤ isoforms. This cross-reactivity is undesirable because of the small difference in size between the two receptor isoforms and the potential for hGR␣ to be posttranslationally modified or degraded into a smaller 90-kDa protein. In the present study we describe the production of an hGR␤-specific antibody termed BShGR. Using this antibody, we investigate the tissue, cellular, and subcellular distribution of the hGR␤ protein.
Materials and Methods Materials
Protease inhibitors were supplied by Boehringer Mannheim (Indianapolis, IN). Dexamethasone was supplied by Steraloids (Wilton, NH). Tran 35 S-Label (1108 Ci/mmol) was purchased from ICN Radiochemicals (Irvine, CA). The peroxidase-labeled goat antirabbit secondary antibody and chemiluminescent detection reagents were obtained from Amersham (Arlington Heights, IL). Biotinylated goat antirabbit IgG was obtained from Vector Laboratories (Burlingame, CA), and the fluorescein-conjugated goat antirabbit IgG was purchased from Molecular Probes (Eugene, OR). Vinylsulfone-activated Sepharose, protein ASepharose CL-4B, and other reagents were purchased from Sigma Chemical Co. (St. Louis, MO).
Cell culture and transfections
HeLa S 3 , CEM-C7, and normal lung epithelial cells (provided by Dr. Paul Nettesheim, NIEHS) were grown as described previously (15, 18) . COS-1, HEK-293, JAR, and Hep G2 cells were grown in DMEM supplemented with 2 mm glutamine and 10% (vol/vol) of a mixture (1:1) of heat-inactivated FCS and calf serum. All cultures were maintained in a 5% CO 2 humidified atmosphere at 37 C and passaged every 3-4 days. For transfection of COS-1 cells, medium was removed from subconfluent cells (1 ϫ 10 6 ) and replaced with fresh DMEM containing 3% serum. Equimolar amounts of pCMVhGR␣ (20 g), pCMVhGR␤ (18.2 g), or pCMV5 (10 g) were prepared as a calcium phosphate precipitate, with the total amount of DNA in each transfection cocktail adjusted to 20 g with salmon sperm DNA. The precipitates were then added to the cells, and after a 5-h incubation, the medium was removed, and the cells were shocked for 30 s with 15% glycerol and then refed with fully supplemented DMEM. Construction of pCMVhGR␣, pCMVhGR␤, and the human cytomegalovirus major intermediate early gene promoter expression vector backbone pCMV5 have been described previously (15) .
Production and purification of the hGR␤-specific antibody BShGR
A peptide corresponding to amino acids 728 -742 at the carboxyterminus of the hGR␤ protein was synthesized and purified by the Micro Protein Chemistry Facility at the University of North Carolina (Chapel Hill, NC). An amino-terminal cysteine was added to the peptide as a linker, and an aliquot of the peptide was conjugated to keyhole limpet hemocyanin to enhance antigenicity. A female New Zealand White rabbit was then immunized with the hGR␤-specific peptide as a mixture (1:1) of free peptide and keyhole limpet hemocyanin-conjugated peptide in Freund's complete adjuvant using a combination of intradermal and sc injections. Subsequently, the rabbit was boosted monthly with a mixture (1:1) of the free peptide and conjugated peptide in incomplete Freund's adjuvant. Serum was collected 2 weeks after each boost and analyzed for hGR␤-specific antibodies. Epitope-purified antiserum was obtained by linking the synthetic peptide to vinylsulfone-activated Sepharose and subjecting the serum to affinity chromatography as described previously (19) .
Western blotting
Confluent cells (COS-1, HeLa S 3 , CEM-C7, HEK-293, JAR, Hep G2, and secondary lung epithelial cells) were harvested and resuspended in buffer containing 10 mm Tris-HCl (pH 8.3), 1 mm EDTA, and a mixture of protease inhibitors (0.1 mm phenylmethylsulfonylfluoride, 1 g/ml aprotinin, 1 m pepstatin, and 1 m leupeptin). Cells were then homogenized by four 10-sec bursts on ice using a Tekmar Ultra Turrax homogenizer (Tekmar Co., Cincinnati, OH), and the homogenate was immediately centrifuged at 165,000 ϫ g in a Beckman 50Ti rotor (Palo Alto, CA) for 1 h at 4 C. Supernatants were collected, mixed with an equal volume of Fairbanks solution [2% SDS, 20 mm Tris-HCl (pH 7.5), 2 mm EDTA, 10% sucrose, and 20 g/ml pyronin Y], boiled for 5 min, and stored at Ϫ70 C. Proteins (75 g for COS-1, 150 g for other cell types) were resolved by electrophoresis through 7.5% SDS-polyacrylamide gels and electrophoretically transferred to nitrocellulose in Tris-glycine buffer [25 mm Tris-HCl (pH 8.3), 150 mm glycine, and 15% methanol] (20, 21) . Membranes were stained with Ponceau S (0.5% in 1% acetic acid) (22) to evaluate loading equivalency and transfer efficiency and blocked overnight at 4 C in Tris-buffered saline [10 mm Tris-HCl (pH 7.4), 150 mm NaCl, and 0.05% Tween-20] containing 10% nonfat dry milk. The blot was then washed in Tris-buffered saline containing 1% nonfat dry milk (TBS-1%) and incubated for 1 h at room temperature with the appropriate dilution of primary antibody in TBS-1% [1:1,000 BShGR for transfected COS-1 cells, 1:500 BShGR for HeLa S 3 and CEM-C7 cells, 1:1,000 for antipeptide hGR antibody 59 (23), 1:1,000 for antipeptide hGR antibody 57 (23) ]. Subsequently, membranes were washed in TBS-1%, reacted for 1 h at room temperature with a horseradish peroxidaselabeled goat antirabbit secondary antibody (1:15,000 in TBS-1%), washed in TBS-1%, reacted with chemiluminescent reagents, and then processed for autoradiography. The human multiple tissue Western blot (Clontech, Palo Alto, CA) contained 75 g protein isolated from different human tissues and was processed as described above. Whole cell lysates (40 g) from various lung, breast, endometrial, bladder, ovary, and melanoma cell lines were kindly provided by Drs. Alicia White and J. Carl Barrett (NIEHS) and analyzed as described above. Blots were stripped by incubating at 55 C for 45 min in 62.5 mm Tris-HCl (pH 6.7), 2% SDS, and 100 mm 2-mercaptoethanol.
In vitro transcription and translation
The hGR␤ cDNA (ϳ3.8 kb) was excised from the expression vector pCMVhGR␤ at the KpnI-BamHI sites and cloned into the KpnI-BamHI sites in the dual promoter vector pT7/T3-18 (Life Technologies, Gaithersburg, MD) to generate pT7/T3-hGR␤. Construction of pT7/T3-hGR␣ has been previously described (24) . These two plasmids were added to the TNT Coupled Reticulocyte Lysate Translation System (Promega Corp., Madison, WI) for in vitro synthesis of the hGR␣ and hGR␤ proteins. The transcription/translation reactions contained 1.0 g pT7/T3-hGR␣ or pT7/T3-hGR␤, 25 l rabbit reticulocyte lysate, 20 m methionine-free amino acids, 4 l Tran 35 S-Label (11.45 mCi/ml), 1 l RNasin ribonuclease inhibitor, 1 l T7 RNA polymerase, and 2 l of the buffer provided by the supplier in a final volume of 50 l. After a 90-min incubation at 30 C, the translation reactions were frozen and stored at Ϫ70 C until used for immunoprecipitation assays.
Immunoprecipitations
HeLa S 3 , CEM-C7, and transfected COS-1 cells were harvested in PBS and lysed using a Dounce homogenizer (Kontes Co., Vineland, NJ) in TENT buffer [20 mm Tris-HCl (pH 7.5), 2 mm EDTA, 150 mm NaCl, and 0.5% Triton X-100 containing protease inhibitors (0.1 mm phenylmethylsulfonylfluoride, 1 g/ml aprotinin, 1 m pepstatin, and 1 m leupeptin]. After the homogenate was centrifuged at 13,000 ϫ g for 5 min at 4 C, the supernatant was collected, and the protein concentration was determined by the method of Bradford (25) using the Bio-Rad (Richmond, CA) protein assay. Proteins (400 g for HeLa S 3 and CEM-C7 cells, 250 g for transfected COS-1 cells) in a final volume of 200 l TENT buffer were precleared with 2.5 l preimmune serum for 15 min at 4 C and then with 40 l protein A-Sepharose beads (133 mg/ml TENT buffer) for 1 h at 4 C. After centrifugation, the supernatant was removed and transferred to a new tube. The appropriate antibody at a 1:100 dilution was added, and each tube was incubated for 2.5 h at 4 C with rotation. For binding immune complexes, 80 l protein A-Sepharose beads were added, and the incubation was continued for an additional 30 min at 4 C with rotation. The protein A-Sepharose-immune complexes were washed three times with 500 l TENT buffer and then resuspended in a buffer containing 10% glycerol, 2% SDS, 0.2 mg/ml bromophenol blue, 62.5 mm Tris-HCl (pH 6.8), and 5% 2-mercaptoethanol. Immunoprecipitated protein was eluted from the protein A-Sepharose by boiling for 5 min and resolved by the method of Laemmli on 8.5% SDS-polyacrylamide gels (26) . After electrophoretically transferring the proteins to nitrocellulose, immunoblotting was carried out as described above using the antipeptide hGR antibody 57. For immunoprecipitation of in vitro translation products, 5.0 l of each translation reaction were added to 200 l TENT buffer and processed as described above. Gels were fixed in 30% methanol-10% acetic acid for 15 min and processed for autoradiography using liquid EN 3 HANCE (DuPont-NEN, Boston, MA).
Immunocytochemistry
HeLa S 3 and transfected COS-1 cells were plated in two-chamber glass slides (ϳ1 ϫ 10 5 cells/chamber slide) and cultured for 24 h in medium containing serum stripped of endogenous glucocorticoids by treatment with dextran-coated charcoal. After a 2-h treatment with or without dexamethasone (1 ϫ 10 Ϫ7 m, final concentration), slides were washed twice in PBS (pH 7.4), fixed for 10 min at room temperature with 2% paraformaldehyde (pH 7.2), washed again in PBS, and then permeabilized in 0.2% Triton X-100 for 20 min. After an additional wash in PBS, the cells were incubated for 20 min in 0.2% normal goat serum followed by an overnight incubation at 4 C with BShGR diluted in PBS (1:8000 for transfected COS-1 cells, 1:1500 for HeLa S 3 cells). Subsequently, the cells were treated for 30 min with biotinylated goat antirabbit IgG at a dilution of 1:200. Immunoreactivity was then visualized by adding avidin-biotin peroxidase (1:200) for 30 min followed by a 10-min reaction with diaminobenzidine-hydrogen peroxide solution.
Surgical sections of adult human tissues, provided by the University of Alabama-Birmingham Tissue Procurement Service, were fixed in buffered formalin and then embedded in paraffin. After deparaffinization, 5-m tissue sections mounted on Superfrost/Plus slides (Fisher Scientific, Pittsburgh, PA) were treated with 3% aqueous hydrogen peroxide to block endogenous peroxidase activity. The sections were treated with 1% swine serum as a blocking reagent and then incubated with a 1:500 dilution of BShGR at 37 C for 30 min. The BioGenix Universal Rabbit kit (BioGenix Laboratories, San Ramon, CA) (biotin/avidin horseradish peroxidase) was used for detection of the primary antibody with diaminobenzidine as chromagen according to the manufacturer's instructions. Control sections for detecting possible nonspecific immunostaining were incubated as described above, except the primary antiserum was replaced with normal rabbit serum. All sections were lightly counterstained with methyl green.
Results

Production and characterization of an hGR␤-specific antibody
The 94-kDa hGR␣ and 90-kDa hGR␤ proteins are identical through amino acid 727, but then diverge, with hGR␣ having an additional 50 amino acids and hGR␤ having an additional nonhomologous 15 amino acids (Fig. 1A) . To produce an antibody specific for the hGR␤ isoform, we synthesized a peptide corresponding to the unique 15 amino acids at the carboxy-terminus of the hGR␤ protein (Fig. 1B) . A rabbit was then immunized with the hGR␤-specific peptide, and after multiple immunizations, serum was collected and epitope purified as described in Materials and Methods. To test the specificity of the epitope-purified antibody (referred to as BShGR for ␤-specific hGR antibody), we initially transfected receptor-negative COS-1 cells with an hGR␣ expression vector (pCMVhGR␣) or an hGR␤ expression vector (pCMVhGR␤). Whole cell extracts were then prepared and analyzed by Western blotting. As shown in Fig. 2A , BShGR specifically detected the 90-kDa hGR␤ protein in the hGR␤-expressing cells. This immunoreactivity was not observed with preimmune serum (data not shown) or with BShGR preabsorbed with the peptide antigen. Moreover, BShGR did FIG. 1. Schematic representation of the hGR␣ and hGR␤ protein isoforms (A) and the hGR␤-specific peptide antigen (B). A, The hGR␣ and hGR␤ protein isoforms are identical through amino acid 727, but then diverge. The functional domains (1 and 2, transactivation domains; DBD, DNA-binding domain; HBD, hormone-binding domain) and putative site of hsp90 interaction are indicated for each isoform. The locations of the peptide epitopes for antipeptide hGR antibodies 59 (amino acids 245-259) and 57 (amino acids 346 -367) are also shown (23) . B, Sequence of the 15-amino acid peptide (corresponding to amino acids 728 -742 at the carboxy-terminus of hGR␤) used to produce the hGR␤-specific antibody BShGR.
not cross-react with hGR␣. The antipeptide hGR antibodies 59 and 57, which were made against epitopes common to both receptor isoforms (see Fig. 1A ) (23) , recognize both proteins and demonstrate that hGR␣ and hGR␤ were expressed at similar levels.
To demonstrate further the specificity of the BShGR antibody, the hGR␤ and hGR␣ proteins were translated in vitro in the presence of radiolabeled methionine. Immunoprecipitations were then performed on the labeled proteins using preimmune serum, antibody 59, BShGR, or BShGR preabsorbed with the peptide antigen (Fig. 2B) . BShGR only immunoprecipitated the hGR␤ protein (lane 3); it did not immunoprecipitate hGR␣ (lane 7). In contrast, antibody 59 immunoprecipitated both receptor isoforms (lanes 2 and 6) . Thus, the Western blot and immunoprecipitation experiments clearly show that BShGR is specific for the hGR␤ protein. These experiments also reveal the major problem associated with using an antibody that recognizes both receptor isoforms for studying expression of the endogenous hGR␤ protein. In COS-1 cells and reticulocyte lysates expressing only the 94-kDa hGR␣ protein, antibodies 59 and 57 also detected a low abundant 90-kDa protein (Fig. 2, A and  B) . This protein appears to be an hGR␣ degradation product but comigrates with hGR␤. Therefore, in cells expressing both hGR␣ and hGR␤, nonspecific hGR antibodies (such as 59 and 57) cannot distinguish the 90-kDa hGR␤ protein from a 90-kDa hGR␣ degradation product.
Expression of the endogenous hGR␤ protein
The hGR␤ mRNA transcript is expressed in many tissues (15, 17) ; however, it is not known whether this message is actually translated into endogenous hGR␤ protein. With the hGR␤-specific antibody BShGR, we now had the reagent to definitively answer this question of fundamental importance. Initially, we performed Western blots on proteins isolated from HeLa S 3 cells (a human cervical carcinoma cell line) and CEM-C7 cells (a human leukemia cell line). These cell lines were chosen because both express the hGR␤ mRNA transcript (15) . Blots processed in parallel were probed with BShGR, BShGR preabsorbed with the peptide antigen, or antibody 57 (Fig. 3, A and B) . In both cell lines, the hGR␤-specific antibody detected a 90-kDa protein that was not observed with preimmune serum (data not shown) or with BShGR preabsorbed with the peptide antigen. The size of the protein and the specificity of the BShGR interaction suggested that this protein was hGR␤.
Antibody 57 detected not only the 94-kDa hGR␣ protein, but also a 90-kDa protein that comigrated with the protein recognized by BShGR (Fig. 3, A and B) . Whether this protein is hGR␤ or a hGR␣ degradation product cannot be determined because antibody 57 cross-reacts with both receptor isoforms (Figs. 1A and 2A) . Regardless of its identity, this 90-kDa protein is less abundant than hGR␣. If one assumes that antibody 57 has the same affinity for the denatured hGR␣ and hGR␤ proteins, this result suggests that hGR␣ is more abundant than hGR␤ in HeLa S 3 and CEM-C7 cells. Consistent with these results, we have shown previously that the hGR␣ mRNA transcripts are more abundant than the hGR␤ message in these two cell lines (15) .
Although the BShGR antibody specifically detected a 90-kDa protein on the Western blot in Fig. 3 , we sought further proof that hGR␤ was expressed in these cells. Our strategy was to analyze proteins immunoprecipitated by BShGR on Western blots using antibody 57. If hGR␤ is present, antibody 57 should detect a 90-kDa protein in the BShGR immunoprecipitates. In this way, hGR␤ can be double probed with two different antibodies recognizing epitopes in different regions of the protein (see Fig. 1A ). The feasibility of this approach was first tested in COS-1 cells transfected with pCMVhGR␣, pCMVhGR␤, or pCMV5 (mock). Immunoprecipitations were performed on whole cell extracts with preimmune serum, antibody 59, BShGR, or BShGR preincubated with the peptide antigen (Fig. 4A) . Antibody 57 successfully detected the 90-kDa hGR␤ protein in the BShGR immunoprecipitates from the hGR␤-transfected cells (compare lanes 3, 7, and 9). This reactivity was not observed with preimmune serum (lane 1) or with BShGR preincubated with the peptide antigen (lane 4).
When this strategy was applied to protein extracts prepared from HeLa S 3 and CEM-C7 cells, antibody 57 detected a 90-kDa protein in the BShGR immunoprecipitates (Fig. 4B , lane 3, both panels). This protein was not immunoprecipitated by nonimmune serum or by BShGR preincubated with the peptide antigen (lanes 2 and 4, both panels), suggesting that this 90-kDa protein is hGR␤. In CEM-C7 cells a higher molecular mass protein (ϳ100 kDa) was also immunoprecipitated by BShGR (lane 3, right panel) . However, the interaction of BShGR with this protein appears to be nonspecific, as this protein was also immunoprecipitated by BShGR preabsorbed with the peptide antigen (lane 4, right panel). As expected, the 94-kDa hGR␣ protein was detected in the antibody 59 immunoprecipitates prepared from transfected COS-1 cells (Fig. 4A, lane 6 ) and from HeLa S 3 and CEM-C7 cells (Fig. 4B, lane 1, both panels) .
Having assured ourselves that the BShGR antibody was reacting specifically with the endogenous hGR␤ protein, we performed Western blots on whole cell lysates isolated from a variety of human cell lines (Table 1) . With the exception of melanoma, SK-OV-3 (ovarian adenocarcinoma), and Hep G2 (hepatocellular carcinoma) cells, the 90-kDa hGR␤ protein was detected by the BShGR antibody in each cell type. Antibody 57 reacted with the 94-kDa hGR␣ protein in all cell lines and with a 90-kDa protein in many of the cells. In general, the 94-kDa hGR␣ protein was much more abundant than this 90-kDa protein. However, in a few cell lines (NCI- H520, NCI-H661, MDA-MB-435S, Ishikawa, and HEC59), the 94-and 90-kDa proteins were made at comparable levels. Whether this 90-kDa protein detected by antibody 57 is hGR␤ or an hGR␣ degradation product cannot be determined at this time, but it raises the possibility that the hGR␣ and hGR␤ proteins are made at similar levels in certain cells.
We next investigated the expression of the hGR␤ protein in human tissues. For this experiment, a Western blot containing proteins isolated from brain, heart, kidney, lung, and skeletal muscle was probed with BShGR. As shown in the left panel of Fig. 5 , a protein consistent in size with hGR␤ is recognized by BShGR in extracts prepared from brain and lung. This protein was weakly detected in heart, but was not observed in kidney and skeletal muscle. As the hGR␤ mRNA transcript has been detected in kidney and skeletal muscle (15, 17) , the hGR␤ protein may be expressed at very low levels in these cells. The blot was then stripped and reprobed with antibody 57, revealing, as expected, expression of hGR␣ in each tissue (Fig. 5, right panel) . With the exception of heart, antibody 57 did not detect a 90-kDa protein in any of the tissues. Assuming that antibody 57 has the same affinity for the denatured hGR␣ and hGR␤ proteins, this result indicates that hGR␤ is less abundant than hGR␣ at the whole tissue level, consistent with the relative levels of the hGR␣ and hGR␤ mRNA transcripts (15) . Interestingly, both BShGR and antibody 57 recognized what appears to be the same 100-kDa protein in heart and skeletal muscle. This muscle-specific protein may be another form of hGR␤ resulting from alterations in the hGR␤ mRNA transcript and/or posttranslational modifications of the hGR␤ protein. Alternatively, this signal may reflect a nonspecific interaction between the antibodies and a protein expressed in the two tissues.
Subcellular distribution of the endogenous hGR␤ protein
We have shown previously using antibody 57 that the hGR␤ protein, in contrast to hGR␣, resides primarily in the nucleus of transfected COS-1 cells independent of glucocorticoid treatment (15) . Unfortunately, these immunocytochemical studies could not be extended to include the endogenous hGR␤ protein because of the cross-reactivity of antibody 57 with hGR␣. Therefore, we tested the ability of BShGR to recognize the native conformation of the hGR␤ protein. For these experiments, COS-1 cells were transfected with pCMVhGR␤, and immunocytochemistry was performed with preimmune serum, BShGR, or BShGR preabsorbed with the peptide antigen (Fig. 6) . BShGR stained the cells that acquired the expression vector, but showed no staining of the untransfected cells (middle panel). Consistent with our earlier observations using antibody 57 (15), hGR␤ was localized preferentially to the nucleus, and its subcellular distribution was unaffected by the administration of glucocorticoids. Significant cytoplasmic staining was observed in some of the cells (left side of middle panel), perhaps reflecting overexpression of the hGR␤ protein. Immunoreactivity was not observed with preimmune serum (upper panel) or with BShGR preabsorbed with the peptide antigen (lower panel), confirming the specificity of the staining. Moreover, BShGR did not stain cells expressing the hGR␣ protein (data not shown).
Because BShGR specifically recognized the native confor- 
Whole cell lysates prepared from various cell lines were analyzed by Western blotting. Blots were probed with the BShGR antibody, stripped, and then reprobed with antibody 57 as described in Materials and Methods. The presence (ϩ) or absence (Ϫ) of hGR␤ and hGR␣ proteins is noted for each cell type. mation of hGR␤, we used this antibody to investigate the cellular and subcellular distribution of the endogenous hGR␤ protein. Immunocytochemistry was conducted initially on HeLa S 3 cells. As shown in Fig. 7 , BShGR stained the nucleus of these cells, and this staining pattern was not altered by glucocorticoids. No significant staining was observed with preimmune serum or with BShGR preabsorbed with the peptide antigen. Similar results were observed in CEM-C7 cells (data not shown). We next performed immunohistochemistry on human tissue sections prepared from lung, thymus, and liver with the BShGR antibody. Heavy immunostaining was observed in the epithelial cells lining the terminal bronchiole of the lung (Fig. 8A) , in the epithelial cells forming the outer layer of Hassall's corpuscle in the thymus (Fig. 8B) , and in the epithelial cells lining the bile duct in the liver (Fig. 8C) . Thymic lymphocytes showed very little staining and hepatocytes showed moderate staining (Fig. 8,  B and D) . In all cases, immunostaining was restricted to the nucleus. Thus, in agreement with our findings for the recombinant hGR␤ protein, the endogenous hGR␤ protein re- 
Discussion
In the present study, we have investigated the expression and subcellular distribution of the hGR␤ protein. To distinguish hGR␤ from the wild-type hGR␣ isoform, we have produced, characterized, and used an hGR␤-specific antibody (BShGR). This antibody binds both the native and denatured conformations of the hGR␤ protein and does not cross-react with hGR␣ under any circumstances. In addition, the interaction of BShGR with hGR␤ is specific, as demonstrated by the inability of the antibody to react with hGR␤ when preincubated with the peptide antigen. Using BShGR on Western blots and in immunoprecipitation experiments, we show that the hGR␤ protein is expressed in a variety of cell lines and tissues. Immunohistochemical analysis of human tissue sections revealed that hGR␤ is expressed at high levels only in certain epithelial cells and that, within cells, hGR␤ is located in the nucleus. Expression of the hGR␤ protein in vivo and its unique cellular and subcellular distribution suggest that hGR␤ has an important physiological function.
In transfected cells, hGR␤ has been shown to function as a dominant negative inhibitor of hGR␣ (15, 17) . Therefore, the relative ratio of the hGR␣ and hGR␤ proteins in vivo may be a critical factor regulating target cell responsiveness to glucocorticoids. Our Western blot data using antibody 57 (which presumably has the same affinity for the denatured hGR␣ and hGR␤ proteins) suggest that hGR␣ is much more abundant than hGR␤ in most cells, consistent with the reported levels of the hGR␣ and hGR␤ mRNA transcripts (15) .
However, our immunohistochemical analysis with BShGR indicates that within tissues, hGR␤ is expressed at high levels in a cell type-specific manner. Epithelial cells lining the terminal bronchiole of the lung, forming the outer layer of Hassall's corpuscle of the thymus, and lining the bile duct of the liver showed strong immunostaining. In contrast, thymic lymphocytes and other epithelial cells in these tissues showed very little immunoreactivity. Moderate immunoreactivity was observed in hepatocytes. Therefore, the relative levels of hGR␣ and hGR␤ may vary considerably among different cells and not at all reflect the ratio determined for the whole tissue. The physiological consequence of cell type-specific differences in the hGR␣ to hGR␤ protein ratio may be cell type-specific differences in glucocorticoid responsiveness.
Exogenous glucocorticoids play an essential role in the acute and chronic therapy of many inflammatory and immune diseases because of their immunosuppressive and antiinflammatory actions. Unfortunately, resistance to the therapeutic effects of glucocorticoids develops in a small proportion of patients being treated for asthma (27, 28) , rheumatoid arthritis (29) , degenerative osteoarthritis (30), ulcerative colitis (31) , transplantation rejection (32), eosinophilic gastritis (33) , and complications from acquired immunodeficiency syndrome (34) . Glucocorticoids have also been used successfully as chemotherapeutic agents in the treatment of many hematological cancers, including Hodgkin's lymphoma, acute lymphoblastic leukemia, and multiple myeloma. Again, the beneficial effect of this therapy is sometimes limited by the occurrence of glucocorticoid-resistant tumors (35, 36) . The molecular mechanisms underlying these tissue-specific glucocorticoid resistant states are largely unknown. However, it is known for many of these glucocor- ticoid-resistant patients that changes in the number and/or ligand-binding properties of hGR␣ cannot account for the observed resistance (28) . Perhaps overexpression of the hGR␤ protein contributes to the glucocorticoid insensitivity. By preventing hGR␣ from binding GREs, forming transcriptionally inactive hGR␣/hGR␤ heterodimers, and/or titrating a coactivator needed by hGR␣ for full transcriptional activity, increased levels of hGR␤ would prevent hGR␣ from activating target genes. Interestingly, a marked reduction in the ability of hGR␣ to bind a GRE was recently demonstrated in patients with glucocorticoid-resistant asthma (37) .
Glucocorticoid insensitivity is observed not only in disease states, but also during normal physiological processes. For example, we and others have shown that genes positively regulated by hGR␣ are unresponsive to glucocorticoids during the G 2 phase of the cell cycle (38, 39) . During development, the chicken retina is resistant to circulating glucocorticoids before embryonic day 6, but thereafter becomes progressively more sensitive even though the level of wildtype GR does not change significantly over this time period (40) . In each case, cell cycle or developmentally regulated induction of hGR␤ might account for the temporary resistance. Indeed, alternative splicing is often regulated in a cell type-specific fashion, in a developmental stage-specific fashion, or in response to specific cellular signals.
Our immunocytochemical analysis of a variety of cells using the BShGR antibody demonstrated that the hGR␤ protein is located predominantly in the nucleus of cells independent of glucocorticoid treatment. The nuclear localization suggests that hGR␤ may regulate gene expression independently of its proposed antagonism of ligand-bound hGR␣. For example, hGR␤ may bind GREs and repress expression of glucocorticoid-responsive genes in the absence of glucocorticoids. In the presence of glucocorticoids, ligandbound hGR␣ would then displace hGR␤ from the GRE and subsequently activate gene expression. Although hGR␤ can bind a GRE (17) , evidence supporting a role for hGR␤ as a constitutive repressor has yet to be found. For example, hGR␤ did not repress the basal activity of the glucocorticoid- responsive mouse mammary tumor virus promoter in transfected COS-1 cells (15) .
In contrast to hGR␤'s constitutive nuclear localization, hGR␣ is generally thought to reside in the cytoplasm of cells in the absence of ligand, but to translocate to the nucleus after hormone treatment (8, 41) . In support of this two-step translocation model, we have shown previously in HeLa S 3 cells that hGR␣ translocates from the cytoplasm to the nucleus in a hormone-dependent manner (23) . However, in this and other immunocytochemical studies performed on hGR␣, significant nuclear staining was observed even in the absence of glucocorticoids (42) (43) (44) . Because the antibodies employed in these experiments recognize both hGR␣ and hGR␤ proteins, the observed nuclear staining may, in fact, reflect expression of hGR␤, and this might account for some of the controversy surrounding the subcellular distribution of hGR␣ (45, 46 ). An hGR␣-specific antibody is needed for the most accurate and definitive determination of hGR␣ compartmentalization.
In the absence of hormone, hGR␣ has been shown to associate with two molecules of hsp90 (9) . The hsp90 molecules are thought to sequester hGR␣ in the cytoplasm of cells by maintaining the receptor in a conformation that masks or inactivates its nuclear localization signals (NLS). Upon hormone binding, the hsp90 molecules dissociate from the receptor, resulting in the unmasking or activation of the NLS, allowing hGR␣ to translocate into the nucleus. The hGR␣ sequences proposed to interact with hsp90 are intact in the hGR␤ protein (4), but whether hGR␤ interacts with hsp90 is not known. The nuclear distribution of hGR␤ makes this an interesting question. The unique carboxy-terminus of hGR␤ may make the site for hsp90 binding inaccessible, resulting in constitutively active NLS and nuclear residence of hGR␤. In support of this hypothesis, hGR␣ mutants incapable of associating with hsp90 localize in the nucleus of cells independent of glucocorticoid treatment (41, 47) . Alternatively, the conformation of hGR␤ may be altered in such a way that the NLS are exposed or activated even when hsp90 is associated with the protein. Cadepond et al. have shown recently that sequences at the carboxy-terminus of hGR␣ exert an inhibitory influence on the NLS (47). Deletion and/or modification of this sequence, as would occur in hGR␤, might inactivate this repression and allow hGR␤ to translocate into the nucleus independent of hsp90 association.
In summary, we have produced an hGR␤-specific antibody termed BShGR, and have used this antiserum to show that the hGR␤ protein is expressed in human cells. In agreement with our findings, the Chrousos laboratory recently reported that the hGR␤ protein is expressed in many different tissues, as revealed by Western blot analysis (48) . It is important to note, however, that the hGR␤ antibodies used by the two independent studies were prepared against different immunogens, and therefore, it is difficult to directly compare the results. We also have demonstrated, for the first time, that the endogenous hGR␤ protein resides in the nucleus of cells and that, within tissues, expression of hGR␤ is most prominent in a certain epithelial cells. These results should provide important clues toward elucidating the physiological function of this hGR splice variant. The immediate goal of future studies will be not only to identify the type of epithelial cell expressing hGR␤ at high levels, but also to investigate epithelial cells in other tissues, such as kidney and digestive tract, for hGR␤ expression. Moreover, it will be important to measure changes in the expression of hGR␤ in physiological and pathophysiological resistant states. With its unique cellular and subcellular distribution, the hGR␤ protein may profoundly alter GR physiology.
